在眼睑缺损的治疗中,板再生一直是一个挑战。临床常用的治疗方法如硬腭黏膜移植不能达到满意的修复效果。组织工程被认为是一种有前途的技术。然而,由于其复杂的结构和脂类分泌功能,组织工程难以实现。三维(3D)打印技术在组织工程中发挥了革命性的作用,因为它可以通过计算机辅助设计(CAD)制造复杂的支架。在这项研究中,将3D打印技术应用于使用聚己内酯(PCL)制造tar板支架是新颖的。将脂肪间充质基质细胞(DMA)脱细胞基质涂覆在支架表面,并对其生物功能进行了进一步研究。将永生化的人SZ95皮脂腺细胞接种在支架上,使得分泌中性脂质用于替代睑细胞。体外实验表明,DMA-PCL支架与皮脂腺细胞具有出色的生物相容性。体内实验显示,DMA-PCL支架上的皮脂腺细胞增殖良好。同时,接种在支架上的皮脂腺细胞在体外和体内分泌丰富的中性脂质。总之,用DMA修饰的3D打印的PCL支架被发现是一种有希望的tar板组织工程的替代品。
Tarsal plate regeneration has always been a challenge in the treatment of eyelid defects. The commonly used clinical treatments such as hard palate mucosa grafts cannot achieve satisfactory repair effects. Tissue engineering has been considered as a promising technology. However, tarsal plate tissue engineering is difficult to achieve due to its complex structure and lipid secretion function. Three-dimensional (3D) printing technology has played a revolutionary role in tissue engineering because it can fabricate complex scaffolds through computer aided design (CAD). In this study, it was novel in applying 3D printing technology to the fabrication of tarsal plate scaffolds using poly-caprolactone (PCL). The decellularized matrix of adipose-derived mesenchymal stromal cells (DMA) was coated on the surface of the scaffold, and its biofunction was further studied. Immortalized human SZ95 sebocytes were seeded on the scaffolds so that neutral lipids were secreted for replacing meibocytes. In vitro experiments revealed excellent biocompatibility of DMA-PCL scaffolds with sebocytes. In vivo experiments revealed excellent sebocytes proliferation on the DMA-PCL scaffolds. Meanwhile, sebocytes seeded on the scaffolds secreted abundant neutral lipid in vitro and in vivo. In conclusion, a 3D-printed PCL scaffold modified with DMA was found to be a promising substitute for tarsal plate tissue engineering.